Polmacoxib

Polmacoxib (trade name Acelex) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015.^[1] It inhibits the enzymes carbonic anhydrase and COX-2. A study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both polmacoxib and celecoxib that suggest a similar cardiovascular risk profile.^[2] Further work by this group developed dose-exposure relationships of polmacoxib to guide clinical development strategies.^[3]

Polmacoxib

Clinical data
Trade names	Acelex
Other names	CG100649
ATC code	M01AH07 (WHO)
Identifiers
IUPAC name 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide
CAS Number	301692-76-2
PubChem CID	9841854
ChemSpider	8017569
UNII	IJ34D6YPAO
KEGG	D10656 Y
ChEMBL	ChEMBL166863
CompTox Dashboard (EPA)	DTXSID901029389
Chemical and physical data
Formula	C18H16FNO4S
Molar mass	361.39 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C
InChI InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23) Key:IJWPAFMIFNSIGD-UHFFFAOYSA-N